Search This Blog

Wednesday, September 15, 2021

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent

 Key Patent for Platform Technology to Treat or Inhibit HBV and HIV Infections

Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology.

The patent, titled, “Methods of Treatment of Infections Using Bacteria,” (Application No. 16/584,644) provides broad protection for the application of the Company’s platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

https://finance.yahoo.com/news/indaptus-therapeutics-receives-notice-allowance-110000625.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.